Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 16/20 | 0.34 |
| ▸ | RAF1 | P04049 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14865710 | 0.90 | ATR (0.39) | ATRPIM1PIM3PIM2 | |
| SCHEMBL14865610 | 0.88 | ATR (0.41) | ATRRAF1BRAFPIM1PIM3 | |
| SCHEMBL14865701 | 0.87 | KDM4E (0.43) | ATRMEN1S1PR1KMT2A | |
| SCHEMBL14866880 | 0.87 | ATR (0.48) | ATR | |
| SCHEMBL14865671 | 0.86 | ATR (0.38) | ATRRAF1BRAFPIM1PIM3 | |
| SCHEMBL14865670 | 0.85 | ATR (0.38) | ATRRAF1BRAFPIM1PIM3 | |
| SCHEMBL14865758 | 0.82 | AXL (0.42) | RAF1BRAF | |
| SCHEMBL14865751 | 0.82 | RAF1 (0.36) | ATRRAF1BRAFPIM1PIM3 | |
| SCHEMBL14865824 | 0.81 | RAF1 (0.36) | ATRRAF1BRAFPIM1PIM3 | |
| SCHEMBL14865900 | 0.81 | ATR (0.38) | ATRRAF1BRAFPIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877759-B2 | Aminopyrazines as ATR kinase inhibitors | Vertex Pharnaceuticals Incorporated (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130095193-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095193-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | ATR 1/4885RAF1 176/4885BRAF 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.